Abstracts tagged "Lupus"

Abstract Number: 644 • 2014 ACR/ARHP Annual Meeting
HM-0523, a Novel Syk Inhibitor Blocks Glomerulonephritis and Extends Life Spans in Lupus Prone MRL/Lpr Mice
Yu Cai¹, Zhipeng Wu¹, Ping Ren¹, Xiaoming Dai¹, Jianlin He¹, Fang Yin¹, Wei Deng¹, Guangxiu Dai¹, Weiguo Su¹ and Xiong Li², ¹Hutchison Medipharma Limited, Shanghai, China, ²Building 4, 720 Cai Lun Road,, Hutchison Medipharma Limited, Shanghai, China
Background/Purpose: Syk is a key mediator of signaling events downstream of a wide array of receptors important for immune functions, including the B cell receptor,…
Abstract Number: 1807 • 2014 ACR/ARHP Annual Meeting
Problems with Fee for Service Payments for Academic Rheumatology Practices: A Need for Payment Reform:
Allen P. Anandarajah¹ and Christopher T. Ritchlin², ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: The current fee-for-service model rewards providers for the volume of services. The model is designed to deliver higher compensation for care of more complex cases. Rheumatologists…
Abstract Number: 719 • 2014 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials
Chris Morehouse¹, Linda Chang², Liangwei Wang³, Philip Brohawn¹, Shinya Ueda⁴, Gabor Illei⁵, Warren Greth³, Stephen Yoo⁶, Lorin Roskos⁷, Yihong Yao⁸, Gabriel Robbie⁹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, Hayward, CA, ³MedImmune, LLC, Gaithersburg, MD, ⁴PK, Astrazeneca, Osaka, Japan, ⁵Clinical Development, Medimmune, Gaithersburg, MD, ⁶Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD
Background/Purpose The pharmacokinetic (PK) and pharmacodynamic (PD) effects of two investigational monoclonal antibodies inhibiting type I IFN signaling - sifalimumab or anifrolumab, specific for IFN-α…
Abstract Number: 642 • 2014 ACR/ARHP Annual Meeting
Treatment with a Glycolipid Ameliorates Lupus Dermatitis and Expands Skin ãä T Cells That Promote the Migration of Langerhans Dendritic Cells
Ram Raj Singh^1,2,3, Anna Eriksson¹, Darshan Randhawa¹ and Miguel-Angel Gutierrez¹, ¹Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, ²Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, ³Interdepartmental Program in Molecular Toxicology, UCLA, Los Angeles, CA
Background/Purpose: Self antigens are taken from tissues to local lymphoid organs to acquire ability to avoid self-reactivity. This important immune function is accomplished by dendritic…
Abstract Number: 2870 • 2014 ACR/ARHP Annual Meeting
B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus
Shaun W. Jackson^1,2, Nicole Scharping¹, Socheath Khim¹ and David Rawlings^1,2, ¹Seattle Children's Research Institute, Seattle, WA, ²Pediatrics, University of Washington, Seattle, WA
Background/Purpose Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and patients with SLE frequently express a “type 1 IFN gene signature”. Type 1…
Abstract Number: 1646 • 2014 ACR/ARHP Annual Meeting
Molecular, Cellular and Histopathologic Assessment of Baseline Characteristics of Sixteen Subjects with Discoid Lupus Erythematosus Prior to Treatment with AMG 811 (anti-IFNγ)
Barbara Sullivan¹, Roberto Guzman², Christopher B. Russell³, Greg Arnold⁴, Michael Boedigheimer¹, Connie Ma⁵, James Chung¹, Victoria P. Werth^6,7 and David A. Martin³, ¹Amgen, Thousand Oaks, CA, ²Pathology, Amgen, Thousand Oaks, CA, ³Medical Sciences, Amgen, Seattle, WA, ⁴Medical Sciences, Amgen, Thousand Oaks, CA, ⁵Clinical Immunology, Amgen, Thousand Oaks, CA, ⁶Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose Discoid Lupus Erythematosus (DLE), the most common chronic cutaneous form seen in LE, includes inflammation leading to scarring, telangiectasias, atrophy, and/or dyspigmentation. Elevated levels…
Abstract Number: 712 • 2014 ACR/ARHP Annual Meeting
Mapping the Disease-Specific Lupusqol to the SF-6D
Rachel Meacock¹, Mark Harrison², Kathleen McElhone³, Janice Abbott⁴, Sahena Haque⁵, Ian N. Bruce⁶ and Lee- Suan Teh⁷, ¹Centre for Health Economics, The University of Manchester, Manchester, United Kingdom, ²University of British Columbia, Vancouver, BC, Canada, ³Royal Blackburn Hospital, Blackburn, United Kingdom, ⁴University of Central Lancashire, Preston, United Kingdom, ⁵University Hospital of South Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁷Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom
Background/Purpose: The LupusQoL is a measure of health-related quality of life (HRQoL) developed specifically to assess the impact of systemic lupus erythematosus (SLE) and its…
Abstract Number: 637 • 2014 ACR/ARHP Annual Meeting
Decreased Inflammatory Dendritic Cells in Lupus-Prone Estrogen Receptor Alpha Knockout (ERαKO) Mice Correlate with Increased Survival
Melissa A. Cunningham¹, Jena R. Wirth², Jackie G. Eudaly³, Jennifer L. Scott⁴, Osama S. Naga³ and Gary S. Gilkeson⁵, ¹Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ²Med/Rheumatology, MUSC, Charleston, SC, ³Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: SLE is a disease that disproportionately affects females. The etiology of the sex bias in this disease is unclear. We previously showed that a…
Abstract Number: 2833 • 2014 ACR/ARHP Annual Meeting
SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study
Sascha Tillmanns¹, Claudia Kolligs¹, David P. D'Cruz², Andrea Doria³, Eric Hachulla⁴, Reinhard E. Voll⁵, Michael Tansey¹ and Klaus Schollmeier⁶, ¹Medical/Clinical, SuppreMol GmbH, Martinsried, Germany, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ³Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁴Medicine Interne et Oncologie Medicale Centre Pole, Lille University, Lille, France, ⁵Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany, ⁶SuppreMol GmbH, Martinsried, Germany
Background/Purpose : SM101, which represents the human soluble non-glycosylated version of the Fcγ receptor IIB, binds to the Fc part of autoimmune complexes and inhibits…
Abstract Number: 1643 • 2014 ACR/ARHP Annual Meeting
Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated?
Rodolfo Perez Alamino¹, Raquel Cuchacovich², Arnold Zea³ and Luis R. Espinoza⁴, ¹internal Medicine, LSUHSC, New Orleans, LA, ²Rheumatology, LSU Medical Center, New Orleans, LA, ³Stanley Scott Cancer Center, New Orleans, LA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA
Background/Purpose Systemic lupus erythematosus (SLE) presents with a wide spectrum of clinical and immunologic abnormalities. On the other hand, exciting data is emerging about the…
Abstract Number: 707 • 2014 ACR/ARHP Annual Meeting
Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody
Samera Vaseer¹, Judith A. James², Aikaterini Thanou³ and Joan T. Merrill⁴, ¹Rheumatology, University Of Oklahoma, Oklahoma City, OK, ²Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Pulmonary involvement is frequent in systemic lupus erythematosus (SLE) and can affect the pleura, pulmonary vasculature, and parenchyma. The prevalence of ILD is lower…
Abstract Number: 485 • 2014 ACR/ARHP Annual Meeting
Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment – a Two-Year Prospective Study in an Interdisciplinary Patient Cohort
Simon Julius Winkelmann¹, Rainald A. Zeuner¹, Dörte Schuldt¹, Johannes Bethge¹, Ulrich Mrowietz², Matthias Laudes¹, Stefan Schreiber¹ and Johann Schroeder¹, ¹1st Medical Dept, University of Kiel, Kiel, Germany, ²Dermatology, Univ Schleswig-Holstein, Kiel, Germany
Background/Purpose: TNFα-Inhibitors are the most widely used biological agents in rheumatic conditions or other chronic inflammatory diseases. Over the last ten years, the occurrence of…
Abstract Number: 2736 • 2014 ACR/ARHP Annual Meeting
Female Specific Increase in T Cell Glycosylation in Lupus
Gabriela Gorelik¹ and Bruce Richardson², ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease characterized by altered T cell signaling. SLE is characterized by epigenetic mechanisms that cause hypomethylation…
Abstract Number: 1629 • 2014 ACR/ARHP Annual Meeting
Added Value of the Determination of Anti-Ribosomal and Anti-Ku Antibodies for Diagnosis of Systemic Lupus Erythematosus
Johannes Schulte-Pelkum¹, Diana Carmona-Fernandes², Maria Jose Santos², Roger Albesa¹ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Rheumatology Research Unit Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Background/Purpose Anti-dsDNA antibodies (aab) are known as important serological marker to aid in the diagnosis of systemic lupus erythematosus (SLE) and are part of the…
Abstract Number: 698 • 2014 ACR/ARHP Annual Meeting
Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus
James S. Andrews¹, Mary Margaretten², Jennifer Barton², Jinoos Yazdany², Ed Yelin² and Patricia P. Katz³, ¹Rheumatology, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, CA
Background/Purpose: Muscle weakness is common and contributes to physical disability in women with systemic lupus erythematosus (SLE). Recently, the Foundation for the National Institutes of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].